Mondesir J M, Bidart J M, Goodman A, Alberici G F, Caille P, Troalen F, Rouesse J, Bohuon C, Gralla R J, Einzig A I
J Clin Oncol. 1985 May;3(5):735-40. doi: 10.1200/JCO.1985.3.5.735.
Drug-dependent antibodies were investigated in patients treated with elliptinium acetate, a cytostatic drug with activity in advanced breast cancer. Retrospective analysis of 83 patients, receiving weekly intravenous elliptinium, showed a high incidence of anti-elliptinium antibodies (20%). Hemolysis occurred among antibody-positive patients, apparently related to the antibody titer. The predictability of anti-elliptinium antibodies for hemolysis and the schedule dependency of antibody development was examined prospectively. Among 42 patients treated weekly for at least three courses, 40% developed antibodies. Of 30 patients receiving elliptinium daily for three days every three weeks, none developed either antibodies or hemolysis. Only antibody positive patients, with titers greater than or equal to 32 were at risk for hemolysis. The possible mechanisms are discussed.
对接受醋酸乙胺嘧啶治疗的患者进行了药物依赖性抗体研究，醋酸乙胺嘧啶是一种对晚期乳腺癌有活性的细胞毒性药物。对83例每周接受静脉注射醋酸乙胺嘧啶的患者进行回顾性分析，结果显示抗醋酸乙胺嘧啶抗体的发生率很高（20%）。抗体阳性患者中发生了溶血，这显然与抗体滴度有关。前瞻性地研究了抗醋酸乙胺嘧啶抗体对溶血的预测性以及抗体产生的给药方案依赖性。在42例每周接受至少三个疗程治疗的患者中，40%产生了抗体。在每三周连续三天每天接受乙胺嘧啶治疗的30例患者中，没有一例产生抗体或发生溶血。只有抗体滴度大于或等于32的抗体阳性患者有溶血风险。文中讨论了可能的机制。
